drugset / Trial / NCT01811953

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

NCT01811953

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and bioequivalence of empagliflozin/metformin (FDC) tablet compared with single tablets empagliflozin and metformin under fed conditions (Part II).

Timeline

Start
2013-03
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule Oral
Subject Empagliflozin/Metformin Unknown Oral
Subject Metformin Small molecule Oral

Indications

No indication recorded.